JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on January 19, 2007; DOI: 10.1124/jpet.106.118216


0022-3565/07/3211-137-147$20.00
JPET 321:137-147, 2007
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.106.118216v1
321/1/137    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rowland, A.
Right arrow Articles by Miners, J. O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rowland, A.
Right arrow Articles by Miners, J. O.

METABOLISM, TRANSPORT, AND PHARMACOGENOMICS

Binding of Inhibitory Fatty Acids Is Responsible for the Enhancement of UDP-Glucuronosyltransferase 2B7 Activity by Albumin: Implications for in Vitro-in Vivo Extrapolation

Andrew Rowland, Paraskevi Gaganis, David J. Elliot, Peter I. Mackenzie, Kathleen M. Knights, and John O. Miners

Department of Clinical Pharmacology, Flinders University and Flinders Medical Centre, Adelaide, Australia

Studies were performed to elucidate the mechanism responsible for the reduction in Km values of UDP-glucuronosyltransferase 2B7 (UGT2B7) substrates observed for incubations conducted in the presence of albumin. Addition of bovine serum albumin (BSA) and fatty acid-free human serum albumin (HSA-FAF), but not "crude" HSA, resulted in an approximate 90% reduction in the Km values for the glucuronidation of zidovudine (AZT) by human liver microsomes (HLM) and UGT2B7 and a 50 to 75% reduction in the S50 for 4-methylumbelliferone (4MU) glucuronidation by UGT2B7, without affecting Vmax. Oleic, linoleic, and arachidonic acids were shown to be the most abundant unsaturated long-chain fatty acids present in crude HSA and in the membranes of HLM and human embryonic kidney (HEK)293 cells, and it was demonstrated that these and other unsaturated long-chain fatty acids were UGT2B7 substrates. Glucuronides with Rf (retention factor) values corresponding to the glucuronides of linoleic and arachidonic acid were detected when HLM and HEK293 cell lysates were incubated with radiolabeled cofactor, and the intensity of the bands was modulated by the presence of crude HSA (increased) and BSA or HSA-FAF (decreased). Oleic, linoleic, and arachidonic acid inhibited AZT and 4MU glucuronidation by HLM and/or UGT2B7, due to an increase in Km/S50 without a change in Vmax. Addition of BSA and HSA-FAF reversed the inhibition. Likewise, coexpression of UGT2B7 and HSA in HEK293 cells reduced the Km/S50 values of these substrates. It is postulated that BSA and HSA-FAF sequester inhibitory fatty acids released during incubations, and the apparent high Km values observed for UGT2B7 substrates arise from the presence of these endogenous inhibitors.


Received December 5, 2006; accepted January 16, 2007.

Address correspondence to: Dr. John Miners, Department of Clinical Pharmacology, Flinders Medical Centre, Bedford Park, SA 5042, Australia. E-mail: john.miners{at}flinders.edu.au




This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
A. Rowland, K. M. Knights, P. I. Mackenzie, and J. O. Miners
Characterization of the Binding of Drugs to Human Intestinal Fatty Acid Binding Protein (IFABP): Potential Role of IFABP as an Alternative to Albumin for in Vitro-in Vivo Extrapolation of Drug Kinetic Parameters
Drug Metab. Dispos., July 1, 2009; 37(7): 1395 - 1403.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
P. J. Kilford, R. Stringer, B. Sohal, J. B. Houston, and A. Galetin
Prediction of Drug Clearance by Glucuronidation from in Vitro Data: Use of Combined Cytochrome P450 and UDP-Glucuronosyltransferase Cofactors in Alamethicin-Activated Human Liver Microsomes
Drug Metab. Dispos., January 1, 2009; 37(1): 82 - 89.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
K. K. Wolf, K. R. Brouwer, G. M. Pollack, and K. L. R. Brouwer
Effect of Albumin on the Biliary Clearance of Compounds in Sandwich-Cultured Rat Hepatocytes
Drug Metab. Dispos., October 1, 2008; 36(10): 2086 - 2092.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
A. Rowland, K. M. Knights, P. I. Mackenzie, and J. O. Miners
The "Albumin Effect" and Drug Glucuronidation: Bovine Serum Albumin and Fatty Acid-Free Human Serum Albumin Enhance the Glucuronidation of UDP-Glucuronosyltransferase (UGT) 1A9 Substrates but Not UGT1A1 and UGT1A6 Activities
Drug Metab. Dispos., June 1, 2008; 36(6): 1056 - 1062.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
A. Rowland, D. J. Elliot, K. M. Knights, P. I. Mackenzie, and J. O. Miners
The "Albumin Effect" and in Vitro-in Vivo Extrapolation: Sequestration of Long-Chain Unsaturated Fatty Acids Enhances Phenytoin Hydroxylation by Human Liver Microsomal and Recombinant Cytochrome P450 2C9
Drug Metab. Dispos., May 1, 2008; 36(5): 870 - 877.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
A. H. Penn and G. W. Schmid-Schonbein
The intestine as source of cytotoxic mediators in shock: free fatty acids and degradation of lipid-binding proteins
Am J Physiol Heart Circ Physiol, April 1, 2008; 294(4): H1779 - H1792.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics.